stockportfolio.pro
Tarsus Pharmaceuticals, Inc. (TARS)
Healthcare · Biotechnology · NasdaqGS
Tarsus Pharmaceuticals, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $57.03M | $25.82M | $17.45M | $182.95M | $451.36M |
| Gross profit | — | — | — | — | $24.86M | $15.85M | $170.13M | $420.68M |
| Net income | $-1.32M | $-4.67M | $-26.81M | $-13.83M | $-62.09M | $-135.89M | $-115.55M | $-66.42M |
| Net margin | — | — | — | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
Source: Tarsus Pharmaceuticals, Inc. SEC filings (10-K).
Explore 8 years of Tarsus Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TARS in your portfolio →
Tarsus Pharmaceuticals, Inc. financial history by metric
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals, Inc. — frequently asked questions
What is Tarsus Pharmaceuticals, Inc.'s revenue?
Tarsus Pharmaceuticals, Inc. (TARS) reported revenue of $451.36M for fiscal year 2025, up 146.7% from the prior year, according to its SEC filings.
Is Tarsus Pharmaceuticals, Inc. profitable?
No — TARS reported a net loss of $-66.42M in fiscal 2025.
What is TARS's P/E ratio?
Tarsus Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Tarsus Pharmaceuticals, Inc. have?
As of fiscal year 2025, TARS carried roughly $72.44M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Tarsus Pharmaceuticals, Inc.'s gross margin?
TARS's gross margin was 93.2% in fiscal 2025 — gross profit of $420.68M on revenue of $451.36M.
What is Tarsus Pharmaceuticals, Inc.'s market cap?
Tarsus Pharmaceuticals, Inc. (TARS) has a market capitalization of about $2.73B, based on the latest data in our nightly-refreshed cache.
When does Tarsus Pharmaceuticals, Inc.'s fiscal year end?
TARS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Tarsus Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.